Seek Labs Expands Oncology Research for Sequence Ablation Therapeutics with Up to $3 Million in Foundation Support
Financial Post ·
Two2Ten Foundation supports the continued development of Seek Labs’ Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis Snyder SALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) — Seek Labs, a Salt Lake City Tech Bio company developing programmable CRISPR-based medicines, today announced an agreement with the Two2Ten Foundation providing up to […]
Two2Ten Foundation supports the continued development of Seek Labs’ Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis Snyder Read More